









Markets
/
Stocks
/
nasdaq-neo
/

Neogenomics Inc

NEO

10.420USD

+0.020+0.19%

Close 11/11, 16:00（ET）Quotes delayed by 15 min

1.34BMarket Cap

LossP/E TTM



Neogenomics Inc

10.420

+0.020+0.19%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Neogenomics Inc

Currency: USD Updated: 2025-11-11

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Neogenomics Inc's Score

Industry at a Glance

Industry Ranking

31 / 78

Overall Ranking

176 / 4608

Industry

Healthcare Providers & Services

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 15 analysts

Hold

Current Rating

12.200

Target Price

+17.31%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Neogenomics Inc Highlights

StrengthsRisks

NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 29.59% year-on-year.

Overvalued

The company’s latest PE is -11.74, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 127.88M shares, decreasing 7.11% quarter-over-quarter.

Held by Chuck Royce

Star Investor Chuck Royce holds 992.59K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-11

The company's current financial score is 7.05, which is lower than the Healthcare Providers & Services industry's average of 7.24. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 187.80M, representing a year-over-year increase of 11.90%, while its net profit experienced a year-over-year increase of 53.28%.

Score

Industry at a Glance

Previous score

7.05

Change



Financials

7.96

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

5.46

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.91

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.76

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.15

Key Metrics

Free cash flow

No Data

Neogenomics Inc's Company Valuation

Currency: USD Updated: 2025-11-11

The company’s current valuation score is 7.83, which is higher than the Healthcare Providers & Services industry's average of 7.09. Its current P/E ratio is -11.74, which is -49.47% below the recent high of -5.93 and -155.38% above the recent low of -29.98.

Score

Industry at a Glance

Previous score

7.83

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 31/78

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-11

The company’s current earnings forecast score is 6.93, which is lower than the Healthcare Providers & Services industry's average of 7.56. The average price target for Neogenomics Inc is 12.50, with a high of 17.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

6.93

Change

Support & Resistance

No Data

Analyst Rating

Based on 15 analysts

Hold

Current Rating

12.200

Target Price

+17.31%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Neogenomics Inc

NEO

CVS Health Corp

CVS

HCA Healthcare Inc

HCA

Teladoc Health Inc

TDOC

Tenet Healthcare Corp

THC

Universal Health Services Inc

UHS

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-11

The company’s current price momentum score is 6.83, which is lower than the Healthcare Providers & Services industry's average of 7.10. Sideways: Currently, the stock price is trading between the resistance level at 11.41 and the support level at 9.42, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.96

Change

-0.13

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.103

Neutral

RSI(14)

59.924

Neutral

STOCH(KDJ)(9,3,3)

65.665

Buy

ATR(14)

0.592

High Vlolatility

CCI(14)

51.622

Neutral

Williams %R

49.774

Neutral

TRIX(12,20)

0.501

Sell

StochRSI(14)

68.477

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

10.346

Buy

MA10

10.135

Buy

MA20

10.210

Buy

MA50

9.118

Buy

MA100

7.864

Buy

MA200

8.737

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-11

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Providers & Services industry's average of 7.03. The latest institutional shareholding proportion is 98.83%, representing a quarter-over-quarter increase of 0.67%. The largest institutional shareholder is The Vanguard, holding a total of 13.87M shares, representing 10.72% of shares outstanding, with 3.14% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

17.77M

-2.83%

The Vanguard Group, Inc.

Star Investors

14.10M

-0.89%

Greenhouse Funds LLLP

7.43M

+57.83%

First Light Asset Management, LLC

6.85M

+13.30%

State Street Investment Management (US)

5.11M

+0.43%

Macquarie Investment Management

4.81M

+2.80%

Dimensional Fund Advisors, L.P.

4.29M

+11.66%

Schroder Investment Management North America Inc.

3.72M

-13.63%

American Century Investment Management, Inc.

3.52M

+5.96%

Millennium Management LLC

3.32M

-50.63%

Risk Assessment

Currency: USD Updated: 2025-11-11

The company’s current risk assessment score is 4.13, which is lower than the Healthcare Providers & Services industry's average of 5.45. The company's beta value is 1.59. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.